Recent advances in the reciprocal regulation of m 6 A modification with non-coding RNAs and its therapeutic application in acute myeloid leukemia.

N6 -methyladenosine (m6 A) is one of the most common modifications of RNA in eukaryotic cells and is involved in mRNA metabolism, including stability, translation, maturation, splicing, and export. m6 A also participates in the modification of multiple types of non-coding RNAs, such as microRNAs, long non-coding RNAs, and circular RNAs, thereby affecting their metabolism and functions. Increasing evidence has revealed that m6 A regulators, such as writers, erasers, and readers, perform m6 A-dependent modification of ncRNAs, thus affecting cancer progression. Moreover, ncRNAs modulate m6 A regulators to affect cancer development and progression. In this review, we summarize recent advances in understanding m6 A modification and ncRNAs and provide insights into the interaction between m6 A modification and ncRNAs in cancer. We also discuss the potential clinical applications of the mechanisms underlying the interplay between m6 A modifications and ncRNAs in acute myeloid leukemia (AML). Therefore, clarifying the mutual regulation between m6 A modifications and ncRNAs is of great significance to identify novel therapeutic targets for AML and has great clinical application prospects.